Pharma firm Assertio Q2 adjusted core profit beats estimates

Assertio Holdings

11/08/2025 21:30

Overview

Assertio Holdings Q2 net product sales fall to $28.8 mln from $30.7 mln yr ago

Adjusted EBITDA for Q2 rises to $5.6 mln, beating analyst expectations, per LSEG data

Co narrows full-year guidance for net product sales and adjusted EBITDA

Outlook

Company narrows full-year net product sales guidance to $108 mln-$118 mln

Assertio updates full-year adjusted EBITDA guidance to $11 mln-$19 mln

Company focuses investment on core assets to enhance growth potential

Assertio ceases Otrexup commercialization to improve operational efficiencies

Result Drivers

ROLVEDON DEMAND - Highest customer demand since acquisition, driven by strong commercial execution

SYMPAZAN GROWTH - Increased prescriber base and prescription demand, supported by additional sales efforts

INDOCIN DECLINE - Sales impacted by generic competition, affecting both volume and pricing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$0.02
-$0.08 (5 Analysts)
Q2 EPS
-$0.17
Q2 Net Income
-$16.40 mln
Q2 Adjusted EBITDA
Beat
$5.60 mln
$2.71 mln (3 Analysts)
Q2 Income From Operations
-$8.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Assertio Holdings Inc is $3.00, about 75.7% above its August 8 closing price of $0.73

Press Release: ID:nGNX6WV4Y7

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)